Genetic Signatures Limited

Equities

GSS

AU000000GSS4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 02:10:43 2024-05-01 am EDT 5-day change 1st Jan Change
0.7 AUD +0.72% Intraday chart for Genetic Signatures Limited +2.94% +60.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genetic Signatures Appoints Interim CEO MT
Genetic Signatures' Sales Drop in Fiscal Q3 MT
Genetic Signatures Secures TGA Approval for Updated EasyScreen Respiratory Pathogen Detection Kit Sale in Australia MT
Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Genetic Signatures Completes Rights Issue MT
Genetic Signatures Closes AU$8 Million Placement MT
Genetic Signatures to Raise AU$15.9 Million via Placement MT
Genetic Signatures Raises AU$16 Million From Share Sale MT
Genetic Signatures Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023 MT
Genetic Signatures Limited Appoints Stephane Chatonsky as Director CI
Genetic Signatures Fiscal Q1 Sales Fall 64% Due to Performance Issue MT
Genetic Signatures Limited(ASX:GSS) dropped from S&P/ASX Emerging Companies Index CI
Genetic Signatures Submits 510(k) Application to the US FDA to Market Parasite Detection Kit in the US; Shares Jump 17% MT
Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Genetic Signatures Appoints CFO/COO MT
Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023 CI
Genetic Signatures Limited Appoints Karl Pechmann as Chief Operating Officer, Effective 26 June 2023 CI
Genetic Signatures Appoints Interim CFO MT
Genetic Signatures Limited Announces Management Changes CI
Genetic Signatures Limited Announces CFO Changes CI
C4X Discovery launches medicine platform on Parkinson's study results AN
Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Genetic Signatures Sees 16% Rise in Fiscal Q1 Sales MT
Genetic Signatures Says Study Shows Detection Kit Has 'Excellent Sensitivity and Specificity' MT
Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Chart Genetic Signatures Limited
More charts
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company’s principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.695 AUD
Average target price
0.75 AUD
Spread / Average Target
+7.91%
Consensus
  1. Stock Market
  2. Equities
  3. GSS Stock
  4. News Genetic Signatures Limited
  5. Genetic Signatures Submits 510(k) Application to the US FDA to Market Parasite Detection Kit in the US; Shares Jump 17%